Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons, filed in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of shareholding changes and does not contain financial performance data.
Material Changes
The material change reported is an increase in share interests for specific individuals following the re-investment of dividends paid on January 8, 2015. The transactions occurred at a price of 1,420.57 pence per share.
- Sir Andrew Witty: 1,544.610 shares
- Mr S A Hussain: 1,831.014 shares
- Dr P J T Vallance: 923.872 shares
- Ms C Thomas: 817.766 shares
- Ms E Walmsley: 749.475 shares
- Mr D S Redfern: 670.949 shares
- Mr S Dingemans: 666.940 shares
- Dr M M Slaoui: 149.766 shares
- Mr P C Thomson: 264.686 shares
- Mr R G Connor: 91.618 shares
- Mrs K Thomson (Connected Person): 62.242 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions.
Investor Verification Points
- Verify the share price of 1,420.57 pence per share on January 8, 2015, to confirm the valuation of the dividend reinvestment.
- Confirm that the share increases listed are solely due to dividend reinvestment plans and not open market purchases.
- Review the full list of Directors and PDMRs to ensure all relevant parties are accounted for in the disclosure.